Pipeline Watch: Phase III Starts With Tesetaxel, Molidustat, Imeglimin
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant
France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative for both the biotech and the US and European licensee, Roivant Sciences.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.